	US 12,403,162 B2
	Use of hemolymph or hemolymph components for the treatment and prevention of inflammation and dry skin
William Patrick Breeding, South Portland, ME (US); and Robert Bayer, Orono, ME (US)
Assigned to Marin Brands Inc., South Portland, ME (US)
Filed by Marin Brands Inc., South Portland, ME (US)
Filed on Dec. 14, 2020, as Appl. No. 17/121,292.
Claims priority of provisional application 62/948,240, filed on Dec. 14, 2019.
Prior Publication US 2021/0177913 A1, Jun. 17, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/612 (2015.01); A61K 35/618 (2015.01); A61K 35/63 (2015.01); A61K 38/17 (2006.01); A61P 17/06 (2006.01); A61K 9/00 (2006.01)

CPC A61K 35/612 (2013.01) [A61K 35/618 (2013.01); A61K 35/63 (2015.01); A61K 38/1767 (2013.01); A61P 17/06 (2018.01); A61K 9/0014 (2013.01)]

18 Claims

1. A method for treating a nonviral, non-neoplastic topical skin condition in a mammal, comprising the steps of:

(a) providing a composition consisting essentially of hemocyanin derived from organisms selected from the group consisting of:

lobster species selected from Nephrops novegicus, Homarus gammarus, Panularis elephas, or Homarus americanus,

crab species selected from Carcinus maenas, Portunus pelagicus, Portunus trituberculatus, Callinectes sapidus, Cancer pagurus, Metacarcinus magister, or Chionoecetes;

crawfish species selected from Procambarus clarkii or Procambarus zonangulus; and

shrimp species selected from Penaeus monodon, Pandalus borealis, Acetes japonicas, or Trachysalambria curvirostris;

wherein hemocyanin is about 20% by weight based on the total weight of the composition; and

(b) administering the composition to the mammal;

whereby the nonviral, non-neoplastic topical skin condition is reduced.